Phenotypes Associated with This Genotype

Genotype
MGI:3767441

• Allelic Composition: Tcrb^tm1Mom/Tcrb^tm1Mom; Tcrd^tm1Mom/Tcrd^tm1Mom
• Genetic Background: B6.129P2-Tcrb^tm1Mom Tcrd^tm1Mom/J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

abnormal transitional stage B cell morphology ( J:187766 )

• ratios of T2:T1 and T3:T1 B cells are increased compared to wild-type mice

decreased plasma cell number ( J:187766 )

• mutants exhibit a reduction in plasma cells (B220low IgD-CD138+)

increased B cell number ( J:187766 )

• in the spleen

increased immature B cell number ( J:187766 )

• 16-18 week old mutants exhibit increased numbers of immature B cells

increased transitional stage T2 B cell number ( J:187766 )

• mutants exhibit an elevation in T2 and to a lesser extent T3 B cells

increased transitional stage T3 B cell number ( J:187766 )

• mutants exhibit an elevation in T2 and to a lesser extent T3 B cells

increased mature B cell number ( J:187766 )

• mutants exhibit an elevation in mature B cells, including both marginal zone and follicular mature B-cell subsets

increased follicular B cell number ( J:187766 )

increased marginal zone B cell number ( J:187766 )

decreased T cell number ( J:187766 )

• in the spleen

decreased IgE level ( J:125656 )

• IgE is not detectable in serum of OVA-treated mutants, but high levels are produced in treated wild-type

decreased IgG level ( J:125656 , J:187766 )

• in OVA-treated mutants, serum IgG is reduced below saline-treated control levels (J:125656)

decreased IgG1 level ( J:125656 )

• IgG1 is not detected in serum after OVA challenge

increased IgM level ( J:187766 )

• mutants exhibit elevated levels of IgM deposition within kidney glomeruli

decreased autoantibody level ( J:187766 )

• decrease in anti-chromatin IgG, anti-histone IgG, and anti-dsDNA IgG

respiratory system

abnormal respiratory system physiology ( J:125656 )

• ovalbumin-sensitized/challenged mice (OVA) are unable to generate an early phase reaction (EPR- initial phase of brochoconstriction) following OVA provocation

hematopoietic system

abnormal transitional stage B cell morphology ( J:187766 )

• ratios of T2:T1 and T3:T1 B cells are increased compared to wild-type mice

decreased plasma cell number ( J:187766 )

• mutants exhibit a reduction in plasma cells (B220low IgD-CD138+)

increased B cell number ( J:187766 )

• in the spleen

increased immature B cell number ( J:187766 )

• 16-18 week old mutants exhibit increased numbers of immature B cells

increased transitional stage T2 B cell number ( J:187766 )

• mutants exhibit an elevation in T2 and to a lesser extent T3 B cells

increased transitional stage T3 B cell number ( J:187766 )

• mutants exhibit an elevation in T2 and to a lesser extent T3 B cells

increased mature B cell number ( J:187766 )

• mutants exhibit an elevation in mature B cells, including both marginal zone and follicular mature B-cell subsets

increased follicular B cell number ( J:187766 )

increased marginal zone B cell number ( J:187766 )

decreased T cell number ( J:187766 )

• in the spleen

decreased IgE level ( J:125656 )

• IgE is not detectable in serum of OVA-treated mutants, but high levels are produced in treated wild-type

decreased IgG level ( J:125656 , J:187766 )

• in OVA-treated mutants, serum IgG is reduced below saline-treated control levels (J:125656)

decreased IgG1 level ( J:125656 )

• IgG1 is not detected in serum after OVA challenge

increased IgM level ( J:187766 )

• mutants exhibit elevated levels of IgM deposition within kidney glomeruli

renal/urinary system

renal glomerular immunoglobulin deposits ( J:187766 )

• mutants exhibit elevated levels of IgM deposition within kidney glomeruli, however IgG deposition in the glomeruli is not seen